Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Mar;7(3):275-83.
doi: 10.1586/14737140.7.3.275.

Dendritic Cell Vaccines for Leukemia Patients

Affiliations
Review

Dendritic Cell Vaccines for Leukemia Patients

Anita Schmitt et al. Expert Rev Anticancer Ther. .

Abstract

Dendritic cells are the most professional antigen-presenting cells to elicit T-cellular responses toward microbial agents and cancer cells. The graft-versus-leukemia effect observed after allogeneic stem cell transplantation strongly suggests that T lymphocytes play a major role in the rejection of leukemic cells. This graft-versus-leukemia effect might be enhanced through dendritic cell vaccination. The characterization of leukemia-specific antigens eliciting immune responses in the autologous host has prompted researchers and clinicians to broaden the spectrum of dendritic cell vaccines to hematological malignancies. Recently, the focus is on acute myeloid leukemia and chronic lymphocytic leukemia. This review summarizes data on the administration of autologous and allogeneic dendritic cells to leukemia patients as an interesting approach in cellular therapy of leukemias.

Similar articles

See all similar articles

Cited by 3 articles

MeSH terms

Feedback